



Krazati in the UAE

The MoHAP named-patient coordination pathway — indicative 2026

ONCOLOGY · KRAS G12C NSCLC

The clinical situation

Krazati (adagrasib) is an FDA-approved oral KRAS G12C inhibitor from Bristol-Myers Squibb (via Mirati) for locally advanced or metastatic NSCLC carrying a KRAS G12C mutation after prior systemic therapy. Taken twice daily at home. Eligibility requires molecular confirmation via NGS on tumour tissue or plasma (liquid biopsy). Monitoring covers GI, hepatic, and QTc side effects via routine laboratory testing and ECG surveillance; in-country infrastructure requirements are modest for oral therapy.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating oncologist confirms KRAS G12C mutation via NGS and documents line history and a written rationale.
- 2 Prescribing facility confirmed.** A UAE oncology practice with routine lab and ECG monitoring capability is identified.
- 3 MoHAP named-patient application.** Clinical rationale, molecular report, patient reference, and chain-of-custody plan are filed (DoH Abu Dhabi / DHA Dubai per facility).
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; ambient-controlled shipment with chain-of-custody.
- 5 Arrival & dispensing.** The hospital pharmacy releases the bottle to the patient with oncologist instructions for twice-daily dosing; refills coordinated on a rolling monthly schedule.

Indicative economics

Reference US cash-pay range: USD 21,000–24,000 per 30-day supply; drug-only reference. Reserve Meds provides a transparent delivered quote at intake.

Indicative first-dose timing

7–14 days from a complete MoHAP application to first dispense, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and MoHAP review including molecular-diagnostic attestation. **Logistics.** Chain-of-custody shipment coordination to your prescribing pharmacy. **Concierge case lead.** Named point of contact for family and physician through intake, first dispense, and refills. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Krazati × UAE first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/krazati-uae.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team